179 related articles for article (PubMed ID: 7585041)
21. Transforming growth factor-beta 1 inhibits tumor necrosis factor-alpha/lymphotoxin production and adoptive transfer of disease by effector cells of autoimmune encephalomyelitis.
Stevens DB; Gould KE; Swanborg RH
J Neuroimmunol; 1994 Apr; 51(1):77-83. PubMed ID: 7512580
[TBL] [Abstract][Full Text] [Related]
22. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.
Angel JB; Saget BM; Walsh SP; Greten TF; Dinarello CA; Skolnik PR; Endres S
AIDS; 1995 Oct; 9(10):1137-44. PubMed ID: 8519449
[TBL] [Abstract][Full Text] [Related]
23. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
24. Multiple sclerosis: TNF revisited, with promise.
Raine CS
Nat Med; 1995 Mar; 1(3):211-4. PubMed ID: 7585035
[No Abstract] [Full Text] [Related]
25. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats.
Rott O; Cash E; Fleischer B
Eur J Immunol; 1993 Aug; 23(8):1745-51. PubMed ID: 8393796
[TBL] [Abstract][Full Text] [Related]
26. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor.
Genain CP; Roberts T; Davis RL; Nguyen MH; Uccelli A; Faulds D; Li Y; Hedgpeth J; Hauser SL
Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3601-5. PubMed ID: 7536938
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones.
Pette M; Muraro PA; Pette DF; Dinter H; McFarland HF; Martin R
J Neuroimmunol; 1999 Aug; 98(2):147-56. PubMed ID: 10430048
[TBL] [Abstract][Full Text] [Related]
28. Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents.
Siegmund B; Eigler A; Moeller J; Greten TF; Hartmann G; Endres S
Eur J Pharmacol; 1997 Feb; 321(2):231-9. PubMed ID: 9063693
[TBL] [Abstract][Full Text] [Related]
29. Rolipram suppresses experimental autoimmune neuritis and prevents relapses in Lewis rats.
Zou LP; Deretzi G; Pelidou SH; Levi M; Wahren B; Quiding C; van der Meide P; Zhu J
Neuropharmacology; 2000 Jan; 39(2):324-33. PubMed ID: 10670428
[TBL] [Abstract][Full Text] [Related]
30. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram.
Nyman U; Müssener A; Larsson E; Lorentzen J; Klareskog L
Clin Exp Immunol; 1997 Jun; 108(3):415-9. PubMed ID: 9182885
[TBL] [Abstract][Full Text] [Related]
31. Differential tumor necrosis factor alpha expression by astrocytes from experimental allergic encephalomyelitis-susceptible and -resistant rat strains.
Chung IY; Norris JG; Benveniste EN
J Exp Med; 1991 Apr; 173(4):801-11. PubMed ID: 1901078
[TBL] [Abstract][Full Text] [Related]
32. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
Weber F; Polak T; Günther A; Kubuschok B; Janovskaja J; Bitsch A; Poser S; Rieckmann P
Ann Neurol; 1998 Jul; 44(1):27-34. PubMed ID: 9667590
[TBL] [Abstract][Full Text] [Related]
33. Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase.
Schmiechen R; Schneider HH; Wachtel H
Psychopharmacology (Berl); 1990; 102(1):17-20. PubMed ID: 2392503
[TBL] [Abstract][Full Text] [Related]
34. Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis.
Greten TF; Sinha B; Haslberger C; Eigler A; Endres S
Eur J Pharmacol; 1996 Mar; 299(1-3):229-33. PubMed ID: 8901027
[TBL] [Abstract][Full Text] [Related]
35. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
Griswold DE; Webb EF; Badger AM; Gorycki PD; Levandoski PA; Barnette MA; Grous M; Christensen S; Torphy TJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
[TBL] [Abstract][Full Text] [Related]
36. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
Kambayashi T; Jacob CO; Zhou D; Mazurek N; Fong M; Strassmann G
J Immunol; 1995 Nov; 155(10):4909-16. PubMed ID: 7594495
[TBL] [Abstract][Full Text] [Related]
37. DAB
Bhopale MK; Hilliard B; Constantinescu CS; Phillips SM; Rostami A
Immunopharmacol Immunotoxicol; 2017 Dec; 39(6):318-329. PubMed ID: 28929835
[TBL] [Abstract][Full Text] [Related]
38. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis.
Murphy AC; Lalor SJ; Lynch MA; Mills KH
Brain Behav Immun; 2010 May; 24(4):641-51. PubMed ID: 20138983
[TBL] [Abstract][Full Text] [Related]
39. Effect of rolipram, a phosphodiesterase inhibitor and potential antidepressant, on the firing rate of central monoaminergic neurons in the rat.
Scuvée-Moreau J; Giesbers I; Dresse A
Arch Int Pharmacodyn Ther; 1987 Jul; 288(1):43-9. PubMed ID: 3662698
[TBL] [Abstract][Full Text] [Related]
40. Mycobacterium bovis bacille Calmette-Guérin infection in the CNS suppresses experimental autoimmune encephalomyelitis and Th17 responses in an IFN-gamma-independent manner.
Lee J; Reinke EK; Zozulya AL; Sandor M; Fabry Z
J Immunol; 2008 Nov; 181(9):6201-12. PubMed ID: 18941210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
